739 related articles for article (PubMed ID: 15531395)
1. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.
Graaf MR; Richel DJ; van Noorden CJ; Guchelaar HJ
Cancer Treat Rev; 2004 Nov; 30(7):609-41. PubMed ID: 15531395
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
3. Farnesyltransferase inhibitors as anticancer agents: current status.
Zhu K; Hamilton AD; Sebti SM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128
[TBL] [Abstract][Full Text] [Related]
4. Potential antitumor effects of statins (Review).
Jakobisiak M; Golab J
Int J Oncol; 2003 Oct; 23(4):1055-69. PubMed ID: 12963986
[TBL] [Abstract][Full Text] [Related]
5. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
Lebowitz PF; Prendergast GC
Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
[TBL] [Abstract][Full Text] [Related]
6. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
7. Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase.
Lingham RB; Silverman KC; Jayasuriya H; Kim BM; Amo SE; Wilson FR; Rew DJ; Schaber MD; Bergstrom JD; Koblan KS; Graham SL; Kohl NE; Gibbs JB; Singh SB
J Med Chem; 1998 Nov; 41(23):4492-501. PubMed ID: 9804689
[TBL] [Abstract][Full Text] [Related]
8. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
Brunner TB; Hahn SM; Gupta AK; Muschel RJ; McKenna WG; Bernhard EJ
Cancer Res; 2003 Sep; 63(18):5656-68. PubMed ID: 14522880
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibitors (FTIs) in myeloid malignancies.
Karp JE; Lancet JE
Ann Hematol; 2004; 83 Suppl 1():S87-8. PubMed ID: 15124688
[TBL] [Abstract][Full Text] [Related]
10. Statins in tumor suppression.
Sassano A; Platanias LC
Cancer Lett; 2008 Feb; 260(1-2):11-9. PubMed ID: 18180097
[TBL] [Abstract][Full Text] [Related]
11. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
[TBL] [Abstract][Full Text] [Related]
12. Rho GTPases: promising cellular targets for novel anticancer drugs.
Fritz G; Kaina B
Curr Cancer Drug Targets; 2006 Feb; 6(1):1-14. PubMed ID: 16475973
[TBL] [Abstract][Full Text] [Related]
13. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone.
Johnson TE; Zhang X; Bleicher KB; Dysart G; Loughlin AF; Schaefer WH; Umbenhauer DR
Toxicol Appl Pharmacol; 2004 Nov; 200(3):237-50. PubMed ID: 15504460
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor.
Sutter AP; Maaser K; Höpfner M; Huether A; Schuppan D; Scherübl H
J Hepatol; 2005 Nov; 43(5):808-16. PubMed ID: 16083991
[TBL] [Abstract][Full Text] [Related]
15. Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase.
Mattingly RR; Gibbs RA; Menard RE; Reiners JJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):74-81. PubMed ID: 12235235
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
Prendergast GC; Oliff A
Semin Cancer Biol; 2000 Dec; 10(6):443-52. PubMed ID: 11170866
[TBL] [Abstract][Full Text] [Related]
17. Statin use and cancer risk: an epidemiologic review.
Friis S; Olsen JH
Cancer Invest; 2006; 24(4):413-24. PubMed ID: 16777695
[TBL] [Abstract][Full Text] [Related]
18. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Horiguchi A; Sumitomo M; Asakuma J; Asano T; Asano T; Hayakawa M
Clin Cancer Res; 2004 Dec; 10(24):8648-55. PubMed ID: 15623649
[TBL] [Abstract][Full Text] [Related]
19. [Signal transduction inhibitor].
Ueda Y; Saijo N
Gan To Kagaku Ryoho; 2001 May; 28(5):591-600. PubMed ID: 11383206
[TBL] [Abstract][Full Text] [Related]
20. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
